Postoperative Prevention of Tumor
Conditions
Brief summary
The main purpose of this study is to explore the PK/PD changes of NMN and DC cells after oral NMN combined with DC cells injection in patients after tumor surgery, and evaluate the biological age of adults, TCR diversity, SiRT1 expression level, SF-36 quality of life, OS, antigen specific immune response (TAA), cytokines and so on. In this study, 20 postoperative tumor patients who meet the entry and excretion criteria were recruited to explore the clinical potential of NMN combined with DC cell vaccine.
Interventions
DRUGOral NMN combined with DC cell vaccine
The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
Sponsors
Shanghai Cell Therapy Group Co.,Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 1\. 18-80 years old, weight ≥ 40kg. * 2\. Patients with malignant solid tumors diagnosed by histology or cytology, who underwent radical resection and completed standard postoperative adjuvant therapy. * 3\. Estimated survival time ≥ 6 months. * 4\. ECOG score 0-1. * 5\. Adequate venous channels, there is no contraindication for peripheral blood monocyte collection. * 6\. Good function of organs and bone marrow.
Exclusion criteria
* 1\. Diabetes. * 2\. Premenopausal or menopause \<1 year. * 3\. Persons who have received hormone replacement therapy within the past 6 months. * 4\. Persons who take vitamin B supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period. * 5\. Unstable weight (\>3% change during the last 2 months before entering the study). * 6\. Significant organ system dysfunction or disease. * 7\. Polycystic ovary syndrome. * 8\. Major psychiatric illness. * 9\. Use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study. * 10\. Metal implants. * 11\. Persons who consume \>14 units of alcohol per week. * 12\. Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival benefit (OS) | Up to 15 years | OS refers to the time from the beginning of randomization to death (for any reason). Patients need to be followed up regularly to keep records. |
| Concentration of double antibodies in peripheral blood | Up to 3 months | — |
| Concentration of NMN (nicotinamide mononucleotide) in peripheral blood | Up to 3 months | — |
| Peripheral blood NAD+ | Up to 3 months | — |
| Cytokines (IL6, TNF- goat, INF- γ, IL-4, IL-10) | Up to 3 months | — |
| T cell depletion index (PD1/Tim-3/lag3) | Up to 3 months | — |
| T cell activation index CD107 | Up to 3 months | — |
| T cell and NK cell function index (INF- γ) and granzyme | Up to 3 months | — |
| High quality Survival benefit Endpoint (DFS) | Up to 15 years | DFS refers to the time from the beginning of treatment to the recurrence of the disease or the death of the patient. Patients need to be followed up regularly to keep records. |
| Distant Metastasis-Free Survival (DMFS) | Up to 15 years | Metastasis-free survival time. Patients need to be followed up regularly to keep records. |
Countries
China
Contacts
Primary ContactJinxing Lou
Backup ContactShuan Liu
Outcome results
None listed